Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Small intestinal obstruction? 92 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 92 reports of Small intestinal obstruction have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.1% of all adverse event reports for PEMBROLIZUMAB.

92
Reports of Small intestinal obstruction with PEMBROLIZUMAB
0.1%
of all PEMBROLIZUMAB reports
16
Deaths
77
Hospitalizations

How Dangerous Is Small intestinal obstruction From PEMBROLIZUMAB?

Of the 92 reports, 16 (17.4%) resulted in death, 77 (83.7%) required hospitalization, and 7 (7.6%) were considered life-threatening.

Is Small intestinal obstruction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 92 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Small intestinal obstruction?

ADALIMUMAB (1,665) INFLIXIMAB (351) VEDOLIZUMAB (341) BEVACIZUMAB (268) RISANKIZUMAB-RZAA (241) DOXORUBICIN (237) CLOZAPINE (211) PREDNISONE (190) CARBOPLATIN (178) FLUOROURACIL (178)

Which PEMBROLIZUMAB Alternatives Have Lower Small intestinal obstruction Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Small intestinal obstruction Reports All Drugs Causing Small intestinal obstruction PEMBROLIZUMAB Demographics